Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Center, Double Blind, Randomized Crossover Study Evaluating the Bioequivalence of VIAject7 Compared to VIAject25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus.

Next Previous
Trial Profile

A Single Center, Double Blind, Randomized Crossover Study Evaluating the Bioequivalence of VIAject7 Compared to VIAject25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin (Primary) ; Insulin lispro
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Biodel

Most Recent Events

  • 15 Mar 2012 Planned patient number 44 added as reported by EudraCT.
  • 01 Mar 2012 Results published in Diabetes, Obesity and Metabolism.
  • 15 Nov 2010 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top